메디프렌드

비상장계속사업자

MEDIFRIEND CORPORATION

성진욱

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

메디프렌드

Business Reg. No. 2748101481 · CEO 성진욱

I.Investment Overview

Target메디프렌드 (2748101481)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명메디프렌드
영문명MEDIFRIEND CORPORATION
대표자성진욱
사업자등록번호2748101481
법인등록번호1801111238682
설립일2019.09.30

V.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW220218.8202211.9202312.4202415.62025
영업이익100M KRW-0.120214.920226.920236.820249.52025
순이익100M KRW-2.120210.420220.52023220244.32025
Item20252024202320222021
자산총계194.6억원191.5억원187.9억원189.7억원191.5억원
부채총계154억원155.3억원153.6억원155.9억원158.1억원
자본총계40.6억원36.3억원34.3억원33.7억원33.4억원
매출액15.6억원12.4억원11.9억원8.8억원2억원
영업이익9.5억원6.8억원6.9억원4.9억원-890만원
순이익4.3억원2억원5,087만원3,634만원-2.1억원

VI.Financial Ratios

FY2025 basis

61.01%

영업이익률

27.88%

순이익률

2.23%

ROA

10.69%

ROE

379.29%

부채비율

20.86%

자기자본비율

VII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

메디프렌드 투심보고서 | Alpha Lenz